Abstract: An apparatus and computerized method classify a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD). A computing device having an input/output interface, one or more processors and a memory is provided. A total kidney volume (TKV), a patient height, and a patient age for the patient is received via the input/output interface. A height adjusted TKV (HtTKV) is determined based on the total kidney volume and the patient height using the one or more processors. An ADPKD classification for the patient is determined based on the height adjusted TKV and the patient age using the one or more processors. The ADPKD classification is provided for the patient via the input/output interface.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: This document relates to methods and materials for treating polycystic kidney disease (PKD) and/or a complication associated with a PKD (e.g., a cardiovascular complication). For example, one or more betaines (e.g., trimethylglycine) can be administered to a mammal having, or at risk of developing, a PKD to treat the mammal.

Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.

Abstract: This document provides methods and materials for using natriuretic polypeptides to reduce the generation of kidney cysts, to reduce the number of kidney cysts, to reduce the size of kidney cysts, and/or to reduce the weight of a mammal's kidneys in mammals with polycystic kidney disease. For example, methods and materials for using natriuretic polypeptides (e.g., BNP) and/or nucleic acid encoding natriuretic polypeptides to reduce kidney cystogenesis and to reduce kidney organ to body weight ratios in mammals with mammals with polycystic kidney disease (e.g., autosomal recessive polycystic kidney disease) are provided.